TY - JOUR
T1 - Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
AU - Jager, Kitty J.
AU - Kramer, Anneke
AU - Chesnaye, Nicholas C.
AU - Couchoud, C. cile
AU - Sánchez-Álvarez, J. Emilio
AU - Garneata, Liliana
AU - Collart, Fréderic
AU - Hemmelder, Marc H.
AU - Ambühl, Patrice
AU - Kerschbaum, Julia
AU - Legeai, Camille
AU - del Pino y Pino, María Dolores
AU - Mircescu, Gabriel
AU - Mazzoleni, Lionel
AU - Hoekstra, Tiny
AU - Winzeler, Rebecca
AU - Mayer, Gert
AU - Stel, Vianda S.
AU - Wanner, Christoph
AU - Zoccali, Carmine
AU - Massy, Ziad A.
PY - 2020/12
Y1 - 2020/12
N2 - The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19–attributable mortality was calculated using propensity score–matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%–21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%–22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%–53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02–1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
AB - The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19–attributable mortality was calculated using propensity score–matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%–21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%–22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%–53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02–1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
KW - COVID-19
KW - attributable mortality
KW - dialysis
KW - kidney replacement therapy
KW - registries
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85095812910&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.kint.2020.09.006
DO - https://doi.org/10.1016/j.kint.2020.09.006
M3 - Article
C2 - 32979369
SN - 0085-2538
VL - 98
SP - 1540
EP - 1548
JO - Kidney International
JF - Kidney International
IS - 6
ER -